Patents by Inventor Michael John Witty
Michael John Witty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230132298Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.Type: ApplicationFiled: December 22, 2022Publication date: April 27, 2023Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
-
Patent number: 11578087Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.Type: GrantFiled: December 1, 2020Date of Patent: February 14, 2023Assignee: Anacor Pharmaceuticals, Inc.Inventors: Tsutomu Akama, David Scott Carter, Jason S. Halladay, Robert T. Jacobs, Yang Liu, Jacob J. Plattner, Yong-Kang Zhang, Michael John Witty
-
Publication number: 20210101916Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.Type: ApplicationFiled: December 1, 2020Publication date: April 8, 2021Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
-
Patent number: 10882872Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.Type: GrantFiled: September 24, 2019Date of Patent: January 5, 2021Assignee: Anacor Pharmaceuticals, Inc.Inventors: Tsutomu Akama, David Scott Carter, Jason S. Halladay, Robert T. Jacobs, Yang Liu, Jacob J. Plattner, Yong-Kang Zhang, Michael John Witty
-
Patent number: 10562921Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.Type: GrantFiled: May 9, 2017Date of Patent: February 18, 2020Assignee: Anacor Pharmaceuticals, Inc.Inventors: Tsutomu Akama, David Scott Carter, Jason S. Halladay, Robert T. Jacobs, Yang Liu, Jacob J. Plattner, Yong-Kang Zhang, Michael John Witty
-
Publication number: 20200017531Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.Type: ApplicationFiled: September 24, 2019Publication date: January 16, 2020Applicant: Anacor Pharmaceuticals, Inc.Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
-
Patent number: 10420772Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.Type: GrantFiled: June 6, 2018Date of Patent: September 24, 2019Assignee: Celgene CorporationInventors: Stacie S. Canan, Natalie Anne Hawryluk, Michael John Witty
-
Patent number: 10214495Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.Type: GrantFiled: July 12, 2016Date of Patent: February 26, 2019Assignee: University of Cape TownInventors: David Waterson, Michael John Witty, Kelly Chibale, Leslie Street, Diego Gonzalez Cabrera, Tanya Paquet
-
Publication number: 20180280399Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.Type: ApplicationFiled: June 6, 2018Publication date: October 4, 2018Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK, Michael John WITTY
-
Publication number: 20180194741Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.Type: ApplicationFiled: July 13, 2015Publication date: July 12, 2018Inventors: DAVID WATERSON, MICHAEL JOHN WITTY, KELLY CHIBALE, LESLIE STREET, DIEGO GONZALEZ CABRERA, TANYA PAQUET
-
Patent number: 10010555Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.Type: GrantFiled: June 1, 2017Date of Patent: July 3, 2018Assignee: Celgene CorporationInventors: Stacie S. Canan, Natalie Anne Hawryluk, Michael John Witty
-
Publication number: 20170348315Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.Type: ApplicationFiled: June 1, 2017Publication date: December 7, 2017Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK, Michael John WITTY
-
Publication number: 20170327519Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.Type: ApplicationFiled: May 9, 2017Publication date: November 16, 2017Applicant: Anacor Pharmaceuticals, Inc.Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
-
Patent number: 9266842Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.Type: GrantFiled: February 15, 2013Date of Patent: February 23, 2016Assignees: MMV MEDICINES FOR MALARIA VENTURE, UNIVERSITY OF CAPE TOWNInventors: Yassir Younis, Kelly Chibale, Michael John Witty, David Waterson
-
Patent number: 9024033Abstract: The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical foimulation for the inhibition of malaria parasite proliferation.Type: GrantFiled: January 17, 2011Date of Patent: May 5, 2015Assignee: MMV Medicines for Malaria VentureInventors: Michael John Witty, David Hardick
-
Publication number: 20150031682Abstract: The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.Type: ApplicationFiled: February 15, 2013Publication date: January 29, 2015Inventors: Yassir Younis, Kelly Chibale, Michael John Witty, David Waterson
-
Publication number: 20120295905Abstract: The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.Type: ApplicationFiled: January 17, 2011Publication date: November 22, 2012Applicant: MMV MEDICINES FOR MALARIA VENTUREInventors: Michael John Witty, David Hardick
-
Patent number: 5883080Abstract: Antiparasitic avermectin derivatives of formula (I), where the broken line represents an optional bond, R.sup.1 and R.sup.4 are independently H, OH, halo, oximino, or an organic radical, R.sup.2, R.sup.6 and R.sup.7 are organic radicals and R.sup.3 is alpha-oleandrosyl or 4'-(alpha-oleandrosyl)-alpha-oleandrosyl optionally substituted at the 4'- or 4"-position, and R.sup.12 and R.sup.13 are independently H, CN, CONH.sub.2, C.sub.1 -C.sub.8 alkyl or aryl optionally substituted with at least one halo, OH, C.sub.1 -C.sub.8 alkylthio group.Type: GrantFiled: January 16, 1998Date of Patent: March 16, 1999Assignee: Pfizer Inc.Inventors: Christopher James Dutton, Stephen Paul Gibson, Michael John Witty
